The Latin America, Middle East and Africa Left Atrial Appendage (LAA) Closure Device Market would witness market growth of 26.1% CAGR during the forecast period (2022-2028).
The most dreaded consequence of atrial fibrillation is a thromboembolic event resulting in a cerebrovascular disaster (CVA). Oral anticoagulant (AC) medication and left atrial appendage (LAA) ligation or excision are the two basic strategies for avoiding stroke in people with atrial fibrillation. LAA devices intended to lower the risk of thromboembolism from the left atrial appendage (LAA) among patients with non-valvular atrial fibrillation are implanted in the heart.
To prevent the LAA thrombus from reaching the systemic circulation, the apparatus mechanically occludes the LAA. Numerous organizations, both new and old, highlight the improving safety of left atrial appendage (LAA) closure devices. In addition, the rapidly increasing use of advanced and cutting-edge technologies in the left atrial appendage closure device market is anticipated to increase sales and profits throughout.
In recent years, the left atrial appendage (LAA) device market has witnessed a rapid expansion as a result of the rapid evolution of clinical expertise, implant effectiveness, and procedural safety, which has led to a rapid increase in the market size of left atrial appendage (LAA) closure devices. Percutaneous occlusion is a very recent and developing technology that is commonly advised for individuals with atrial fibrillation and an elevated risk of stroke.
The UAE healthcare industry has developed to satisfy the population's changing requirements and the country's aspiration to become a regional medical tourism hub. The COVID-19 outbreak has prompted the UAE to recommit to healthcare investment. Due to this, the adoption of left atrial appendage closure devices would also be expedited within healthcare facilities across the country. This factor is increasing the growth of the regional left atrial appendage closure devices market.
The Brazil market dominated the LAMEA Left Atrial Appendage (LAA) Closure Device Market by Country in 2021; thereby, achieving a market value of $88.6 million by 2028. The Argentina market is poised to grow at a CAGR of 26.8% during (2022 - 2028). Additionally, The UAE market would witness a CAGR of 25.7% during (2022 - 2028).
Based on Application, the market is segmented into Geospatial Mapping, Disaster Management, Energy & Resource Management, Surveillance & Monitoring, and Others. Based on End User, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Left Atrial Appendage (LAA) Closure Device Market is Predict to reach $4 Billion by 2028, at a CAGR of 19.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
By End-use
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 